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AHIAbstract Background: Sleep-disordered breathing (SDB) is highly prevalent in patients with
advanced chronic kidney diseases (CKDs).
Objective: To describe and compare the prevalence, severity, and patterns of SDB and associated
nocturnal hypoxia among patients with advanced CKD, hemodialysis (HD) patients, and control
group.
Methods: Forty patients were recruited from outpatient nephrology clinics and hemodialysis
units. Patients were stratiﬁed into two groups: conservative (n= 25), and HD (n= 15). 30 healthy
individual enrolled as the control group. All participants completed polysomnography (PSG).
Results: Case control study of forty CKD patients (15 HD and 25 conservative) [13(86.7%) and
20 (80%) men, mean age 62.73 ± 5.43 and 55.76 ± 9.03 year, BMI 40.83 ± 8.75 and
36.12 ± 16.53 kg/m, mean ESS 18.46 ± 3.20 and 17.84 ± 2.79), respectively, and 30 healthy par-
ticipants served as the control. The prevalence of SDB in CKD was 33/40(82.5%). In the conserva-
tive group, AHI was 148.84 ± 147/h, [80% obstructive, 13% central, and 5% mixed apnea].
Among these conservative groups with OSA patients, 56% had severe, 31% moderate, and
12.5% mild OSA. While in the HD group, AHI 133.26 ± 111/h, [84.6% obstructive, 7.7% central,
and 7.7% mixed apnea]. Among these HD groups with OSA, 63% had severe, 27% moderate, and
9% mild OSA. GFR was signiﬁcantly correlated with AHI and ODI (r= 0.315, P< 0.05,
r= 0.506, P< 0.001) respectively. AHI correlated with urea concentration (r= 0.094,
P< 0.05). Increased creatinine, and decreased eGFR were signiﬁcant risk factors of severe OSA.
Predictors that reduced renal function were, decreased TST, delayed latency to REM sleep, and
increased AHI.
Conclusions: Severe OSA was highly prevalent among CKD. Urea was the stronger predictor of
increased AHI.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. All rights reserved.d.
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The prevalence of chronic kidney diseases (CKDs) is increas-
ing worldwide, and there is increasing evidence linking
sleep-disordered breathing (SDB) with kidney disease [1].
Sleep-disordered breathing refers to a wide spectrum of
sleep-related breathing abnormalities; those related to an
increase in upper airway resistance include snoring, upper
airway resistance syndrome, and obstructive sleep apnea–
hypopnea syndrome [2]. CKD describes patients with a
chronically decreased glomerular ﬁltration rate (GFR) or
other evidence of kidney damage. There are different levels
of CKD, which provide the basis of an international classiﬁ-
cation system [3]. Sleep disorders are common in patients
with chronic renal failure [4,5]. Sleep apnea occurs in 50%
of patients with end stage renal disease (ESRD); [6] which
is considerably higher than in the general population [7].
The potential importance of sleep disordered breathing in
the CKD population is highlighted by the worldwide mortal-
ity in end stage renal disease (ESRD) patients as high as 20
per cent per annum. It is also possible that sleep apnea accel-
erates the deterioration of kidney function in patients with
CKD either indirectly by increasing systemic BP, inﬂamma-
tory cytokines and sympathetic nervous system activity all
of which have been proposed to reduce kidney function
[8–10] or directly through the effect of hypoxia on the kidney
[11,12]. Severe hypoxic events in obstructive sleep apnea
(OSA) might lead to kidney damage [13]. Sleep disorders tend
to be under-recognized by renal healthcare providers [13].
Polysomnography remains the gold standard for diagnosing
sleep-disordered breathing. Monitoring should be done in
conjunction with a comprehensive sleep medicine evaluation.
Portable monitoring can be performed in a patient who can-
not be safely transported for laboratory polysomnogram [14].
Subjects and methods
Forty patients with CKD, stages 5 as deﬁned by an estimated
glomerular ﬁltration rate [eGFR] < 15 mL/min/1.73 m
according to the National Kidney Foundation Staging
System [15], attended outpatient nephrology clinics and the
hemodialysis unit of the Internal Medicine Department of
the Menouﬁya University Hospital from January 2011 to
2013. And 30 apparent healthy control subjects
[eGFR] > 90 mL/min/1.73 m were invited to participate in
the study. Exclusion criteria included supplemental oxygen
use, tracheostomy, CPAP therapy and inability to give
informed consent. The study was approved by the Health
Research Ethics Board of the Menouﬁa University. Informed
consent was obtained from all participants. Patients were
stratiﬁed according to their estimated glomerular ﬁltration
rate (eGFR) at the time of the study visit and classiﬁed into
two groups based on the National Kidney Foundation stag-
ing system as follows: CKD (eGFR <13 mL/min/1.73 m2
not on dialysis, n= 25), ESRD (on hemodialysis, n= 15),
eGFR was calculated using the Chronic Kidney Disease Epi-
demiology Collaboration (CKD-EPI) equation [15]. All
patients completed a standardized sleep history questionnaire
which included a history of snoring, witnessed apnea during
sleep and nocturnal choking, un-refreshing sleep, morning
headaches, insomnia, and memory impairment. Additionally,the questionnaire surveyed demographic information and
medical history, including a history of obesity (body mass
index [BMI]P 30 kg/m), hypertension, cardiovascular disease
(angina, myocardial infarction, coronary artery bypass sur-
gery, or congestive heart failure), cerebrovascular disease
(stroke or transient ischemic attack), diabetes, chronic
obstructive pulmonary disease (COPD), and medications.
All patients completed the Epworth sleepiness score (ESS)
[16]. The ESS is a self-administered questionnaire designed
to measure the general level of daytime sleepiness. Patients
rate on a scale of 0–3 how likely they are to fall asleep in 8
different situations that are commonly encountered. Total
ESS scores range from 0 to 24, with higher scores indicating
more subjective daytime sleepiness. Speciﬁcally, an ESS score
>10 is considered indicative of subjective daytime sleepiness
[16]. All CKD patients performed an attended, overnight
PSG in the sleep laboratory unit in chest Department Menou-
ﬁa University. Dialysis patients were asked to perform the
overnight study on a dialysis-free day. Overnight PSG was
performed using (Embla S4000 Medcare, Iceland).The system
has Somnologica studio 3.3.2 software, electrodes and cable-
stor record the electroencephalogram (EEG), electrooculo-
gram (EOG),electromyogram (EMG) of the chin and
bilateral tibialis anterior muscles, and electrocardiogram
(ECG). Airﬂow was measured using nasal and oral thermis-
tors, and a nasal pressure transducer. Respiratory effort
was monitored with respiratory inductive polysomnography
belts with thoracic and abdominal locks. Oximetry was mea-
sured using a disposable ﬁnger probe (oximeter ﬂex sensor
8000J) placed on the index ﬁnger. Snoring was recorded using
snore microphones (piezo snoring sensor) attached to the
neck. Body position was monitored using a body position
sensor. All studies were analyzed by trained PSG technicians
and sleep physicians using the criteria of Rechtscaffen and
Kales [17], and in close concordance with scoring updates
given by the American Academy of Sleep Medicine [18].The
traditional Rechtscaffen and Kales terminology for the 5
sleep stages (i.e. stages 1, 2, 3, 4, and REM sleep, with stages
1 and 2 collectively referred to as ‘‘light sleep’’, stages 3 and 4
collectively referred to as ‘‘deep sleep’’) were used in this
study. Apneas were scored when there was a complete cessa-
tion of airﬂow or P90% drop in the peak thermal sensor
excursion for at least 10 s. Hypopneas were scored when there
was a drop in nasal pressure by P30% of baseline lasting at
least 10 s with a P4% desaturation from pre-event baseline,
or when there was a drop in nasal pressure signal excursion
by P50% of baseline lasting at least 10 s with a P3% desat-
uration from pre-event baseline. The apnea–hypopnea index
(AHI) which is the number of apnea–hypopnea events per
hour was determined after the exclusion of periods with
movements, which were considered to be wake periods. An
apnea without chest or abdominal movements was classiﬁed
as CSA and apnea with chest and abdominal movements
was classiﬁed as OSA. Hypopneas were considered to be
obstructive when there was evidence of upper airway obstruc-
tion, such as snoring, paradoxical respiratory band movement
or inspiratory ﬂow limitation through the nasal cannula; cen-
tral hypopnea, in contrast, was associated with in-phase respi-
ratory movements and no evidence of inspiratory ﬂow
limitation. SDB was considered to be central if greater than
50% of apnea/hypopnea events were central and obstructive
if greater than 50% were obstructive [19].
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Data were collected, tabulated, statistically analyzed by the
computer using SPSS version 16, two types of statistics were
done:
1- Descriptive statistics: Quantitative data are expressed to
measure the central tendency of data and diversion
around the mean, mean (x) and standard deviation
(SD) Qualitative data are expressed in number and
percentage.
2- Analytic statistics: ANOVA test was used for compari-
son of more than two groups of normally distributed
variables;
Kruskal–Wallis test was used for comparison of more than
two groups of normal distributed variables; Student t test was
used to compare between two groups of quantitative data nor-
mally distributed; Mann–Whitney test was used to compare
between two groups of quantitative data not normally distrib-
uted; Chi square test and chi-square (v2) tests were used to
compare categorical outcomes. Pearson correlation (r) was
used to detect association between quantitative variables.
Binary logistic regression was done for signiﬁcant risk fac-
tors) P value >0.05 was considered statistically non signiﬁ-
cant. – P value 60.05 was considered statistically signiﬁcant.
– P value 60.001 was considered statistically highly
signiﬁcant).Results
The characteristics for all studied participants are shown in
(Table 1). 15 patients attending HD unit and 25 patients with
stage 4 kidney disease (conservative group) were completed the
study (13/15 (86.7%) and 20/25 (80%) men, 8/15 (53.3%) and
15/25 (60%) current smokers, mean age 62.73 ± 5.4 and
55.76 ± 9.03 year, neck circumference 41.63 ± 3.22 and
39.06 ± 3.76 cm, BMI 40.83 ± 8.75 and 36.12 ± 16.53 kg/
m2, the mean ESS 18.46 ± 3.204 and 17.84 ± 2.79) respec-
tively (Table 1). 30 apparent healthy participants served as
control (23/30 (76.7%) men, mean age 54.83 ± 11.25 year,
neck circumference 30.07 ± 2.66 cm, BMI 30.63 ± 9.47 kg/
m2, the mean ESS 6.50 ± 2.59). There were statistically
signiﬁcant differences between the studied groups regardingTable 1 Showed socio-demographic data, anthropometric measure
Parameter Dialysis N= 15 Conservative N=
Age (years) 62.73 ± 5.43 55.76 ± 9.03
Male (No & %)
Female (No & %)
13(86.7%)
2(13.3%)
20(80%)
5(20%)
Smoker (No & %)
Non smoker (No & %)
8(53.3%)
7(47.7%)
15(60%)
10(40%)
BMI (kg/m) 40.83 ± 8.75 36.12 ± 16.53
Neck circumference 41.63 ± 3.22 39.06 ± 3.76
ESS (0–24) 18.46 ± 3.204 17.84 ± 2.79
P1 between dialysis and conservative group, P2 between dialysis and consocio-demographic and anthropometric measurements. Sex
distribution was statistically insigniﬁcant among the studied
group. Patients with the conservative group were the youngest
and the greatest proportion of current smokers (P< 0.001),
while the HD group had signiﬁcantly higher BMI, neck cir-
cumference and ESS (P< 0.05), compared with control group
(Table 1). Among patients group, 20 (50%) were diabetic, 22
(55%) hypertensive, 24 (60%) IHD, 15(37.5%) cerebrovascu-
lar disease, and 20 (50%) COPD. The prevalence of hyperten-
sion, DM, and cardiovascular diseases were highly signiﬁcant
P< 0.001 in those with the conservative group (Table 2).
Sleep related symptoms for all patients groups are displayed
in (Table 2). The most common symptoms were EDS
22(55%), snoring 20(50%), insomnia 18(45%), while morning
headache and nocturea were the least encountered symptoms
12(30%). There were highly signiﬁcant differences P< 0.001
in the prevalence of reported snoring, EDS, insomnia, morning
headaches, and nocturea among HD compared with the con-
servative group (Table 2).The laboratory characteristics for
all studied patients groups (HD and conservative) are dis-
played in Table 3. There were statistically signiﬁcant differ-
ences between the HD and conservative group regarding
serum urea, creatinine, Ionized Ca++, % of HCT, and
eGFR. Sleep efﬁciency and monitoring time were sufﬁciently
long to capture important respiratory events. Polysomnogra-
phy Parameters and their unadjusted differences across study
groups are shown in (Table 4). Total sleep time (TST), REM
latency from sleep onset, AHI in supine position, PLM index,
(%) of lowest oxygen saturation, AHI, oxygen desaturation
index (ODI), % of snoring time in TST, % of REM in TST,
total AHI in NREM, and Total AHI in REM were signiﬁ-
cantly different in the HD and conservative groups compared
with control group. There were no signiﬁcant differences in
sleep onset, Sleep latency to S1 or S2, deep sleep latency
(SWS), total arousal index, ﬂow limitation index, % of sleep
in supine position, total limb movement, and average oxygen
saturation across three groups (Table 4). The prevalence of
SDB in CKD was 33/40 (82.5%).Conservative group had more
participants with SDB compared with the HD (20/25 [80%];
vs. 13/15 [86.6%]; P< 0.05), respectively. 5/25(20%); and 2/
15(13.4%) were normal (AHI <5) across both groups, respec-
tively (Table 5). Sleep apnea was predominantly obstructive;
very few central and/or mixed apneas were recorded among
any of the participants (Table 6). In the conservative group,
Mean AHI was 148.84 ± 147.79/h, (16/20 (80%) obstructivement, and Epworth sleepiness score (ESS).
25 Control N= 30 ANOVA P value
54.83 ± 11.25 3.716 <0.05
23(76.7%)
7(24.3%)
0.625* >0.05
– 16.6 <0.001
30.63 ± 9.47 3.633 <0.05
30.07 ± 2.66 2.21 <0.05
6.50 ± 2.59 146.39 P< 0.001
Post hoc LCD
P1 > 0.05
P2 < 0.001
P3 < 0.001
trol group, P3 between control and conservative group.
Table 2 Showed co-morbid diseases and symptoms of patients group.
Parameter (No&%) Dialysis (n= 15) Conservative (n= 25) Total X2 P value
DM Yes 6(40%) 14(56%) 20(50%) 32.7 <0.001
No 9(60%) 11(44%) 20(50%)
Hypertension Yes 6(40%) 16(64%) 22(55%) 32.7 <0.001
No 9(60%) 9(36%) 18(45%)
Cardiovascular Yes 9(60%) 15(60%) 24(60%) 0.0 1.0
No 6(40%) 10(40%) 16(40%)
Cerebrovascular disease Yes 5(33.7%) 10(40%) 15(37.5%) 0.18 >0.05
No 10(67.3%) 15(60%) 25(62.5%)
COPD Yes 7(46.7%) 13(52%) 20(50%) 0.11 >0.05
No 8(53.3%) 12(48%) 20(50%)
Snoring Yes 6(40%) 14(56%) 20(50%) 32.7 <0.001
No 9(60%) 11(44%) 20(50%)
Excessive daytime sleepiness Yes 6(40%) 16(64%) 22(55%) 32.7 <0.001
No 9(60%) 9(36%) 18(45%)
Insomnia Yes 9(60%) 9(36%) 18(45%) 32.7 <0.001
No 6(40%) 16(64%) 22(55%)
Morning headache nocturia Yes 12(80%) 0(0) 12(30%) 31.7 <0.001
No 3(20%) 25(100%) 28(70%)
Table 3 Showed laboratory characteristics of the studied patients group.
Parameter Dialysis N= 15 Conservative N= 25 T test P value
Creatinine (mg/dl) 3.606 ± .955 2.564 ± .591 4.278 <0.001
Urea (mg/dl) 218.667 ± 73.070 156.08 ± 78.52 2.503 <0.05
Na+ (mmol/l) 134.973 ± 6.316 135.960 ± 5.898 0.499 >0.05
K+ (mmol/l) 4.5133 ± .691 4.544 ± .834 0.12 >0.05
Ionized Ca++ (mg/dl) 3.906 ± .648 4.572 ± .382 4.09 <0.001
HCT (%) 30.106 ± 2.322 32.756 ± 2.280 3.533 <0.05
GFR mL/min/1.73 m 6.613 ± 2.350 13.52 ± 4.102 7.31 <0.001
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Among these conservative groups with OSA patients, 9/16
(56%) had severe OSA (AHI >30/h), 5/16 (31%) had moder-
ate OSA (AHI 15–30/h), and 2/16 (12.5%) had mild OSA
(AHI 5–15/h).While in the HD group, Mean AHI was
133.26 ± 111.48/h, 11/13 (84.6%) obstructive apnea, 1/13
(7.7%) central apnea, and 1/13 (7.7%) mixed apnea). Among
these HD groups with OSA patients, 7/11 (63%) had severe
OSA (AHI >30/h), 3/11 (27%) had moderate OSA (AHI
15–30/h), 1/11 (9%) had mild OSA (AHI 5–15/h) (Tables 5–
7). Age correlated with urea concentration (r= 0.353,
P< 0.05), serum creatinine (r= 0.337, P< 0.05) and GFR
(r= 0.615, P< 0.001), GFR signiﬁcantly correlated with
BMI, AHI or ODI (r= 0.351, P< 0.05, r= 0.315,
P< 0.05, r= 0.506, P< 0.001), respectively (Table 11).
Regarding correlation between AHI and markers of renal
function, signiﬁcant negative correlations were found between
AHI and eGFR mL/min per 1.73 m2 (r= 0.032, P< 0.05)
(Table 9). AHI correlated with urea concentration
(r= 0.094, P< 0.05), but interestingly, not serum creatinine
(r= 0.120, P< 0.05) (Table 9). There was highly signiﬁcant
positive correlation between AHI and DI (r= 0.612,
<0.001) (see Table 10). PLM signiﬁcantly correlated with
Serum K level (r= 0.100, P< 0.05) (Table 8). Serum Na
level correlated with AHI, ODI and hypopnea(r= 0.323,
P< 0.05, r= 0.394, P< 0.05, r= 0.411, P< 0.001),
respectively (Table 11). Using Binary logistic regression modelincluding risk factors regarding CKD, advanced age, increase
BMI, diabetes, hypertension, smoking, elevated serum urea
and creatinine level, decrease ionized Ca, HCT and decreased
GFR were risky by: 0.940, 0.960, 0.030, 0.004, 0.032, 0.999,
0.464, 0.652, 1.145, 1.035, respectively (Table 12). Other Inde-
pendent variables included TST,REM Latency from sleep
onset, AHI, ODI, % of snoring time from TST, % of REM
in TST, AHI in REM and NREM, PLM and lowest oxygen
saturation. Predictors that accelerate the deleterious effect on
the renal system included, decrease in total sleep time. Delayed
sleep latency to the REM sleep, increase in AHI relative to
supine position, low (eGFR), smoking, and decreased
HCT%, while at older age, higher body mass index, diabetes,
hypertension and other sleep parameters were not signiﬁcant
across ourmodels (Tables 13 and 14). The relationship between
severe OSA (AHI >30 and ODI >30) on one side and risk
factors on the other side was tested by multivariate logistic
regression analysis, AHI and oxygen desaturation were
regarded as dependant variables. And the independent vari-
ables included age, BMI, diabetes, hypertension, Smoking,
serum urea and creatinine level, ionized Ca level, HCT, and
GFR were risky by 1.007, 1.043, 0.488, 0.818, 0.402, 1.070,
0.996, 1.042, 0.839, and 3.68 times, respectively. Among tradi-
tional risk factors, advanced age, and increased BMI were all
associated with severe obstructive sleep apnea. Additionally,
increased serum creatinine, decreased ionized calcium and
decrease eGFR were associated with severe OSA (Table 15).
Table 4 Polysomnography parameters across all studied groups.
Parameters Hemodialysis (HD) N= 15 Conservative (CKD) N= 25 Control N= 30 Kruskal–Wallis
test
P value Post hoc
Total sleep time (TST) (min) 254.27 ± 71.165 288.21 ± 91.046 352.90 ± 114.433 5.856 <0.05 P1 > 0.05 P2 < 0.05 P3 < 0.05
Sleep onset (minute) 61.366 ± 66.209 51.020 ± 43.119 63.800 ± 18.744 0.681 >0.05
Sleep latency to S1 (min) 33.140 ± 57.887 22.326 ± 26.838 0.649 >0.05
Sleep latency to S2(minute) 37.806 ± 60.548 35.174 ± 40.639 0.027. >0.05
Deep sleep latency SWS (min) 99.580 ± 113.176 263.05 ± 830.224 0.569 >0.05
REM latency from sleep onset (min) 33.13 ± 114.388 66.91 ± 90.413 114.10 ± 116.583 3.320 <0.05 P1 > 0.05
P2 < 0.05
P3 > 0.05
Spontaneous arousals index 27.760 ± 29.562 40.124 ± 26.920 34.733 ± 30.31 0.859 >0.05
Flow limitation index % total 13.98 ± 16.511 9.980 ± 13.503 11.213 ± 10.92 0.435 >0.05
% of sleep in supine position 44.41 ± 29.510 50.05 ± 31.905 50.60 ± 34.512 0.197 >0.05
A+H/h in supine position 50.50 ± 30.526 39.96±.9.211 2.303±.1.867 30.608 <0.001 P1 > 0.05
P2 < 0.05
P3 < 0.05
Total limb movement 15.82 ± 170.360 11.97 ± 124.607 – 0.678 >0.05
PLM movement 39.00±.62.249 30.52 ± 59.719 .100±..402 4.798 <0.05 P1 > 0.05
P2 < 0.05
P3 < 0.05
Average oxygen saturation (%) 90.33±.7.239 89.93 ± 16.807 92.63±.5.542 0.451 >0.05
Lowest oxygen saturation (%) 77.93±.11.732 79.08 ± 8.484 85.266±.8.76 4.344 <0.05 P1 > 0.05 P2 < 0.05 P3 < 0.05
AHI 133.266±.111.480 148.840±.147.791 2.303±.1.867 16.389 <0.001 P1 > 0.05
P2 < 0.001
P3 < 0.001
Oxygen desaturation events (OD) 203.33±.137.832 157.96±.148.999 3.880±.3.186 21.847 <0.001 P1 > 0.05
P2 < 0.001
P3 < 0.001
% of snoring time in TST 133.35±.155.843 181.11±.218.921 2.563±.6.499 10.416 <0.001 P1 > 0.05
P2 < 0.001
P3 < 0.001
%of REM in TST 11.820±.12.553 21.240±.19.902 9.700±.8.259 4.725 <0.05 P1 < 0.05
P2 > 0.05
P3 < 0.001
Total AHI in NREM 25.273±.22.806 30.704±.26.364 3.760±.7.297 14.330 <0.001 P1 > 0.05
P2 < 0.001
P3 < 0.001
Total AHI in REM 25.053±.17.273 31.384±.26.436 6.833±.11.169 12.008 <0.001 P1 > 0.05
P2 < 0.05
P3 < 0.001
P1 between dialysis and conservative group, P2 between dialysis and control group, P3 between control and conservative group.
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Table 5 Showed different types of sleep related breathing disorders among studied patient’s group (mean ± SD).
Parameters Dialysis n= 15 Conservative n= 25 T test P value
CKD with SDB N= 33/40(82.5%) 13/15(86.6%) 20/25(80%) <0.05
CKD without SDB N= 7/40(7.5%) 2/15(13.4%) 5/25(20%) 0.29 >0.05
Light sleep 1 (mean ± SD) 59.767 ± 18.790 57.952 ± 24.553 0.246 >0.05
Deep sleep 1 (mean ± SD) 28.433 ± 22.318 20.296 ± 23.561 1.078 >0.05
OSA (mean ± SD) 60.400 ± 73.889 67.440±.82.712 0.073 >0.05
Central apnea (mean ± SD) 1.666±.2.894 6.680±.24.867 0.599 >0.05
Mixed apnea (mean ± SD) 3.133±.5.370 15.520±.43.202 1.209 >0.05
Hypopnea 68.066±.65.238 59.200±.60.678 0.189 >0.05
Table 6 Showed different types of sleep related breathing disorders among studied patient’s group (No & %).
CKD OSA CSA Mixed Chi square test P value
Conservative 16/20 (80%) 3/20 (13%) 1/20 (5%) 29.85 <0.001
(HD) 11/13 (84.6%) 1/13 (7.7) 1/13 (7.7%) 23.08 <0.001
Table 7 Showed different grades of OSA among studied patient’s group (No&%).
CKD Mild OSA AHI >5 Moderate OSA AHI 15–30 Severe OSA AHI >30 Chi square test P value
Conservative 2/16 (12.5%) 5/16 (31%) 9/16 (56%) 6.94 <0.05
(HD) 1/11 (9%) 3/11 (27%) 7/11 (63%) 7.93 <0.05
Table 8 Showed correlation between PLM and different
KFT, serum electrolytes and sleep parameters.
PLM R P value
Creatinine (mg/dl) 0.185 >0.05
Urea (mg/dl) 0.164 >0.05
Na (mmol/l) 0.362 >0.05
K (mmol/l) 0.100 <0.05
Ca (mg/dl) 0.163 >0.05
HCT% 0.179 >0.05
GFR mL/min per 1.73 m2 0.146 >0.05
AHI 0.012 >0.05
DI 0.044 >0.05
Table 9 Showed correlation between AHI and different
parameters.
AHI R P value
Creatinine (mg/dl) 0.120 >0.05
Urea (mg/dl) 0.094 <0.05
Na (mmol/l) 0.210 >0.05
K (mmol/l) 0.002 >0.05
Ca (mg/dl) 0.055 >0.05
HCT% 0.133 >0.05
GFR mL/min per 1.73 m2 0.032 <0.05
PLM 0.12 >0.05
DI 0.612 <0.001
Table 10 Showed correlation between DI and different
parameters.
DI R P value
Creatinine (mg/dl) 0.069 >0.05
Urea (mg/dl) 0.045 >0.05
Na (mmol/l) 0.394 <0.05
K (mmol/l) 0.068 <0.05
Ca (mg/dl) 0.221 >0.05
HCT (%) 0.207 >0.05
GFR mL/min per 1.73 m2 0.153 <0.05
PLM 0.044 >0.05
AHI 0.612 <0.001
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Sleep related breathing disorders (SDB) tend to be under-rec-
ognized by renal healthcare providers [13]. The aim of our
study is to describe and compare the prevalence, severity,and patterns of SDB and associated nocturnal hypoxia among
patients with advanced CKD, hemodialysis (HD) patients, and
the control group (see Figs. 1 and 2).
In the current work the prevalence of SDB in CKD was 33/
40(82.5%). Sleep apnea was predominantly obstructive; very
few central and/or mixed apneas were recorded among any
of the participants. In the conservative group, mean AHI
was 148.84 ± 147.79/h, (80%) obstructive apnea, and (13%)
central apnea, (5%) mixed apnea). Among these conservative
groups with OSA patients, 56% had severe OSA (AHI >30/
h), 31% had moderate OSA (AHI 15–30/h), and 12.5% had
mild OSA (AHI 5–15/h).While in the HD group, mean AHI
was 133.26 ± 111.48/h, (84.6%) obstructive apnea, (7.7%)
central apnea, and (7.7%) mixed apnea). Among these HD
groups with OSA patients, 64% had severe OSA (AHI >30/
h), 27% had moderate OSA (AHI 15–30/h), and 9% had mild
OSA (AHI 5–15/h). A systematic review of 17 studies in
patients with end stage renal disease (ESRD) indicated that
‘‘sleep disordered breathing’’ was one of their most common
Table 11 Showed the correlation between kidney function testes and different sleep parameters.
GFR r P value HCT r P value Ca r P value K r P value Na r P value Urea r P value Creatinine r P value Parameter
0.615
<0.001
0.274
>0.05
0.299
>0.05
0.141
>0.05
0.094
>0.05
0.353
<0.05
0.337
<0.05
Age
0.351
<0.05
0.036
>0.05
0.225
>0.05
0.102
>0.05
0.084
>0.05
0.053
>0.05
0.102
>0.05
BMI
0.315
<0.05
0.111
>0.05
0.100
>0.05
0.013
>0.05
0.323
<0.05
0.106
>0.05
0.004
>0.05
Apneahypoapnea index
0.146
>0.05
0.066
>0.05
0.212
>0.05
0.011
>0.05
0.189
>0.05
0.185
>0.05
0.069
>0.05
Obstructive apnea
0.162
>0.05
0.036
>0.05
0.103
>0.05
0.211
>0.05
0.044
>0.05
0.200
>0.05
0.083
>0.05
Central apnea
0.077
>0.05
0.164
>0.05
0.236
>0.05
0.231
>0.05
0.112
>0.05
0.040
>0.05
0.061
>0.05
Mixed apnea
0.114
>0.05
0.237
>0.05
0.112
>0.05
0.239
>0.05
0.411
<0.05
0.114
>0.05
0.087
>0.05
Hypoapnea
0.506
<0.001
0.207
>0.05
0.125
>0.05
0.068
>0.05
0.394
<0.05
0.045
>0.05
0.069
>0.05
Oxygen desaturation
0.039
>0.05
0.193
>0.05
0.003
>0.05
0.167
>0.05
0.001
>0.05
0.013
>0.05
0.272
>0.05
Flow limitation index
0.143
>0.05
0.080
>0.05
0.031
>0.05
0.009
>0.05
0.152
>0.05
0.192
>0.05
0.004
>0.05
Light sleep
0.020
>0.05
0.276
>0.05
0.003
>0.05
0.040
>0.05
0.104
>0.05
0.173
>0.05
0.143
>0.05
Deep sleep
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Kraus [21] reported that the prevalence of sleep apnea in such
patients ranges from 50 to 70 percent. Previous studies have
evaluated the prevalence of sleep apnea in CKD. Markou
et al. [22] reported a 31.4% prevalence of sleep apnea in a
cross-sectional study of 35 patients with CKD, but their study
was limited by a small sample size and the absence of compar-
ative groups with eGFR <60 and ESRD. Further, patients
with cardiovascular disease were excluded; limiting the gener-
alizability of their ﬁndings because cardiovascular comorbidi-
ties are common in this patient population [23,24]. Sim et al.
[25] reported an increased risk for sleep apnea in patients with
mildly reduced eGFR. However, the prevalence of sleep apnea
was low (2.5%), and the absence of BMI data precluded
adjustment for the known association between obesity and
sleep apnea [26], Canales et al. [27] declared an increased prev-
alence (27%) of sleep apnea in a cohort of elderly men but
found no association with kidney function. Sakaguchi et al.
[28] reported an increased prevalence (32%) of sleep apnea
in 100 patients with CKD in Japan, which may not be gener-
alizable to non-Asian populations. Roumelioti et al. [29]
reported a high prevalence (22.5%) of severe sleep apnea in
89 patients with CKD but used historical control data where
kidney function was undeﬁned. Finally, in all of these studies,
eGFR was determined using the Modiﬁcation of Diet and
Renal Disease Study equation, which is unreliable at eGFR
P60, introducing potential misclassiﬁcation bias [30–33].
Two recent American studies investigated the prevalence of
SDB in patients with different degrees of chronic kidney dis-
ease and reported a prevalence of 26–57% [32]. Cornette
et al. [32] had evaluated the prevalence of SDB in a large group
of European patients undergoing CHD. 71 patients attending
six CHD centers in the western part of Switzerland completed
the study (50 men, mean age 61.8 ± 15.4, neck circumference
40.6 ± 4.6 cm, BMI 25.7 ± 4.8 kg/m2). Mean AHI was
23.9 ± 20.4/h, (18% obstructive apnea, 8.5% central apnea,and 2.4% mixed apnea). Among these 71 patients, 31% had
severe SDB (AHI >30/h), 23.9% had moderate SDB (AHI
15–30/h), 31% had mild SDB (AHI 5–15/h) and 14.1% were
normal (AHI <5/h). Our study had limitations. First, the
potential for selection bias exists as patients attending the
nephrology clinics may have been more likely to participate
if they suspected they had sleep apnea. We tried to limit the
potential impact of this on our ﬁndings by emphasizing that
sleep related complaints were not required for recruitment.
Although such a bias existed, a higher prevalence of sleep
related breathing disorders (SDB) in CKD patients was the
case. Second, we did not examine patients with the full spec-
trum of kidney function, ranging from those with eGFR
P60 to ESRD. Third, we recruited a relatively small sample
from a renal population representative of the CKD (stage 4–
5) and ESRD populations only. Forth cardiovascular, cerebro-
vascular diseases, hypertension, and DM were not excluded,
expanding generalizability of their ﬁndings because these
comorbidities are common in this CKD population and had
a potential effect on SDB. Markou et al., Canales et al., Rou-
melioti et al., and Young et al. [22,27,29,26] showed that the
prevalence of OSA in this population has ranged from 27%
to 54%, which is considerably higher than the general popula-
tion [7]. These ﬁndings were in harmony with our results. Kim-
mel et al. [20] postulated that there was growing evidence that
obstructive sleep apnea (OSA) was common in patients with
chronic kidney disease who do not require chronic dialysis
(CKD) 1. Unruh [34] mentioned that OSA is exceedingly com-
mon among individuals with end-stage renal disease, affecting
an estimated 50% of patients [34]. But in a cross-sectional
study of 158 individuals with suspected OSA, Fleischmann
et al. [35] found that stage 3 CKD (deﬁned as an eGFR
<60 ml/min/1.73 m2) was a statistically signiﬁcant predictor
of central sleep apnea events but not OSA events. However,
data are limited by small sample size and selection bias because
study participants were drawn from individuals with suspected
Table 12 Showed binary logistic regression between risk
factors regarding dialysis and conservative group.
Variables Exp (B) 95.0% CI for EXP (B)
Lower Upper
Age (year) .940 .823 1.075
BMI (weight/hight) .960 .896 1.029
DM .726 .030 17.873
HTN .231 .004 14.847
Smoking 2.409 .032 183.660
Creatinine mg/dl .464 .079 2.734
Urea mg/dl .999 .987 1.011
Ionized Ca .652 .074 5.776
HCT% 1.145 .761 1.723
GFR (mL/min per 1.73 m) 1.035 .616 1.738
Constant 403.74
Table 15 Showed Binary logistic regression between risk
factors.
Parameters Exp (B) 95.0% C.I. for EXP (B)
Lower Upper
Age (year) 1.007 .883 1.149
BMI (weight/hight) 1.043 .966 1.125
Diabetes .488 .006 38.426
Hypertension .818 .011 63.016
Smoking .402 .005 29.486
Creatinine mg/dl 1.070 .165 6.947
Urea mg/dl .996 .983 1.010
Ionized Ca mg/dl 3.683 .411 32.990
HCT% .839 .536 1.312
GFR (mL/min/1.73 m2) 1.042 .587 1.850
Constant .768
122 H.A. El-Aatty et al.OSA. The coexistence of OSA in patients with CKD is likely to
have clinical relevance. In addition to causing impairment of
sleep quality and daytime function [9], furthermore, OSA
may accelerate the deterioration of kidney function in patients
with CKD either directly, through the effect of hypoxia on the
kidney [9], or indirectly, by increasing systemic blood pressure,
inﬂammatory cytokines, and sympathetic nervous system
activity [11,12]. Gbemisola and Sylvia [36] concluded that
OSA is associated with hypoxemia and sleep fragmentation,
which activates the sympathetic nervous system, the renin
angiotensin-aldosterone system, alters cardiovascularTable 13 Showed multivariate analysis between dialysis group and
Variables B Wald
Total sleep time .000 .000
REM latency from sleep onset .009 .059
Apnea–Hypopnea (AH) .047 .209
Oxygen desaturation events .012 .112
%snoring time in TST .029 .432
%of REM in TST .062- .037
Total AHI NREM index .079 .096
AHI relative to supine position .004 .000
PLM movement .049 .257
Lowest oxygen saturation .072 .015
Table 14 Showed multivariate analysis between the conservative gr
Variables B Wald
Total sleep time .000 .000
REM latency from sleep onset .006 .038
Apnea–Hypopnea (AH) .054 .269
Oxygen desaturation events .013 .123
Snoring time of TST .027 .435
% REM of TST .083 .060
Total AHI REM index .058 .066
AH/h in supine position .007 .001
PLM movement .048 .284
Lowest oxygen saturation .118 .024hemodynamics, and results in free radical generation. In turn,
a variety of deleterious processes such as endothelial dysfunc-
tion, inﬂammation, platelet aggregation, atherosclerosis, and
ﬁbrosis are triggered, predisposing individuals to adverse car-
diovascular events and likely renal damage [37]. Independent
of obesity, OSA is associated with glomerular hyperﬁltration
and may be an independent predictor of proteinuria, a risk fac-
tor for CKD progression. OSA may mediate renal damage via
several mechanisms, and there is a need to better elucidate the
impact of OSA on incident renal disease and CKD progression
[38]. Fluid retention may lead to airway edema nocturnalthe control group.
Sig. Exp (B) 95.0% C.I. for EXP (B)
Lower Upper
.999 1.000 .953 1.049
.807 1.009 .939 1.084
.648 .955 .782 1.165
.738 .988 .919 1.061
.511 .971 .891 1.059
.848 .940 .497 1.776
.757 .924 .561 1.523
.983 1.004 .672 1.500
.612 .952 .789 1.150
.902 .930 .295 2.933
oup and the control group.
Sig. Exp (B) 95.0% C.I. for EXP (B)
Lower Upper
.992 1.000 .952 1.051
.846 1.006 .947 1.068
.604 .948 .774 1.161
.726 .987 .919 1.061
.510 .973 .898 1.055
.807 .921 .475 1.786
.798 .943 .603 1.475
.972 .993 .678 1.456
.594 .953 .799 1.137
.878 .889 .198 3.989
Figure 1 Showed signiﬁcant negative correlation between GFR and AHI.
133.266
203.33
133.35
148.84
157.96
181.11
2.3033.882.563
-10
10
30
50
70
90
110
130
150
170
190
210
Dialysis conservativecontrol
apnea hypopnea
oxygen desaturation
snoring time 
Figure 2 AHI, DI, and snoring time in three different studied groups.
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of SDB (5), Roumelioti et al. [5] found that potential patho-
physiological mechanisms and mediators for the higher preva-
lence of SDB in the CKD and HD population included,
increased pharyngeal cross-sectional area and abdominal cir-
cumference, over hydration, metabolic acidosis, high levels of
proinﬂammatory cytokines, C-reactive protein, and triglycer-
ides. Moreover sleep apnea increases the risk of hypertension
[39], cardiovascular disease, and cerebrovascular disease
[40,41], all of which are important and highly prevalent com-
plications of both CKD and ESRD [42–44]. These complica-
tions of sleep apnea are predominantly mediated through
nocturnal hypoxia, which has been associated with elevated
nocturnal BP [38], left ventricular hypertrophy [37], and
adverse cardiovascular outcomes in patients with ESRD
[42,38]. Although it is likely that sleep apnea may have asimilar impact on clinical outcomes in patients with CKD,
Shahar et al. [45] announced that the OSA has been indepen-
dently associated with cardiovascular diseases, including
hypertension [46], coronary heart disease, heart failure, and
stroke [47]. Each of these factors can have a deleterious impact
on renal function; thus, it is not surprising that OSA is a com-
mon clinical problem for patients with chronic kidney disease
(CKD). Nieto et al. [46] postulated that the OSA is also asso-
ciated with hypertension, another important risk factor for
CKD progression, particularly proteinuric CKD. In the pres-
ent work AHI correlated with urea concentration (r= 0.094,
P< 0.05), and GFR (r= 0.032, P< 0.05) but interestingly,
not serum creatinine level (r= 0.120, P > 0.05). However
oxygen desaturation index (ODI) had been demonstrated to
be independently associated with declined eGFR and acceler-
ated loss of kidney function (r= 0.153, P< 0.05). This
124 H.A. El-Aatty et al.ﬁnding was concordant with Markou et al. [22] they conducted
a cross-sectional cohort study of 35 individuals with stable
CKD, deﬁned by a creatinine clearance less than 40 mL/min,
AHI correlated with urea concentration (r= 0.35,
P= 0.037), but not creatinine clearance (r= 0.12,
P= 0.506). After excluding diabetic patients, Markou et al.
[22] found that urea became an even stronger predictor of
AHI (r= 0.608, P= 0.001), and a statistically signiﬁcant rela-
tionship between creatinine clearance and AHI emerged
(r= 0.5, P= 0.012). An important limitation of that study
was the small sample size and absence of a control group. In
another study of obese adults, increasing severity of OSA
was associated with higher serum creatinine [47]. Agrawal
et al. [47] emphasized that the markers of renal function,
including serum urea concentration and creatinine clearance,
also has been associated with OSA in CKD. Thus, there may
be an association between renal function and sleep apnea.
Marrone’s group [48] analyzed 8,112 patients in the European
Sleep Apnea Database (ESADA) seen for suspected OSA at 24
centers with polysomnography or cardiorespiratory polygra-
phy and who had data available to calculate eGFR. Overall,
8.5% of the cohort had an eGFR below 60 ml/min/1.73 m2,
all in the range of stage 3 kidney disease. That measure of kid-
ney function correlated with Apnea–Hypopnea Index by home
polygraphy (P= 0.008) but not by the more rigorous sleep
study. The opposite was true for oxygen desaturation index,
which correlated with eGFR on polysomnography
(P= 0.013) but not polygraphy. Mean and lowest oxygen sat-
uration were signiﬁcantly linked with eGFR by both types of
sleep study [48] the chronic hypoxia hypothesis suggests that
chronic ischemic damage in the tubule-interstitium of the kid-
ney is the ﬁnal common pathway for the development of
ESRD [12,49] if such a process is already under way in patients
with CKD, it is possible that ongoing nocturnal hypoxia will
amplify the effect and accelerate the decline in kidney function.
If so, identiﬁcation and treatment of nocturnal hypoxia may
provide a potential disease-modifying intervention that could
delay or halt the progression of CKD to ESRD. Controver-
sially, an observational study showed that Severe hypoxic
events in obstructive sleep apnea (OSA) might lead to kidney
damage, though the sleep disorder appeared to be only a minor
contributor overall, and the researchers reported that Mean
oxygen saturation was not a signiﬁcant predictor overall in
the multivariate analysis, nor were there consistent correla-
tions between eGFR and Apnea–Hypopnea Index [50]. These
data imply that reduced kidney function may contribute to the
pathogenesis of sleep apnea independently of traditional risk
factors for sleep apnea and coexisting vascular disease. Both
ﬂuid overload [50] and altered chemical control of breathing
[51,52] have been proposed to cause sleep apnea in patients
with ESRD. It is possible that similar mechanisms contribute
to the pathogenesis of sleep apnea in patients with CKD prior
to starting dialysis. In the present work, the striking ﬁnding
was the high prevalence of nocturnal hypoxia
203.33 ± 37.832 in patients with HD. Furthermore, only a
portion of the nocturnal hypoxia in the HD groups was attrib-
uted to sleep apnea (mean AHI was 133.26 ± 11.48), suggest-
ing that the pathogenesis was partly due to non-apneic factors.
Co morbid pulmonary and cardiac diseases are possible mech-
anisms that can alter the mechanics and control of respiration,
where 7/15(46.7%) of HD participants were COPD and 9/
15(60%) were IHD. In other studies [51,53,54] multivariateanalysis revealed that COPD was associated with nocturnal
hypoxia, but cardiovascular disease and use of sedatives and
narcotics were not. Other potential causes, such as ﬂuid over-
load, should be considered in future studies. We can expect
that if a patient has a very important drop in oxygen satura-
tion, it may in some way worsen his kidney function, especially
if he has comorbidities. In the present work, among traditional
risk factors, advanced age, and increased BMI were all associ-
ated with severe obstructive sleep apnea. Additionally,
increased serum creatinine, decreased ionized calcium and
decreased eGFR were associated with severe OSA. Predictors
that accelerate the deleterious effect on the renal system
included, decrease in total sleep time. Delayed sleep latency
to the REM sleep, increase AHI relative to the supine position,
low (eGFR), smoking, and decreased HCT%, while older age,
higher body mass index, diabetes, hypertension and other sleep
parameters were not signiﬁcant across our models. Marrone
[55] noted that, predictors of a low estimated glomerular ﬁltra-
tion rate (eGFR) included older age, female gender, and higher
body mass index across most models, while diabetes was signif-
icant in polysomnography-tested patients, and hypertension
was signiﬁcant in nocturnal cardiorespiratory polygraphy-
tested patients. Marrone [55] noted that, potential mechanisms
for a causal link to kidney damage could be intermittent
hypoxia, metabolic abnormalities, hypertension, and sympa-
thetic hyperactivity, the most likely explanation was via vascu-
lar damage in kidneys from hypoxic events. He announced
that kidney is a vulnerable area of the body provided that there
were comorbid conditions like diabetes and hypertension; it
could accelerate the deleterious effect on the renal system.
Our data revealed that, the most common sleep symptoms
were EDS 22(55%), insomnia 20(50%), and snoring 20(50%)
among CKD patients. The lack of excessive daytime sleepiness
in a signiﬁcant proportion of OSA patients with CKD18
(45%) has been reported in other speciﬁc OSA populations,
including those with stroke [56], heart failure [57], hyperten-
sion [57,33], and end-stage renal disease [58]. There are a num-
ber of potential explanations for this observation that we can
speculate on. First, it may reﬂect selection bias if the presence
of sleep symptoms is not equally important in the recruitment
of patients to the groups that are compared. Second, the com-
plaint of subjective sleepiness may be overshadowed by other
symptoms associated with chronic disease, such as anxiety or
chronic fatigue, or side effects of their treatment such as med-
ications. Third, the comorbid disease itself may hinder the
development of excessive sleepiness through competing bio-
logic mechanisms, such as augmented sympathetic activity in
patients with chronic heart failure. Regardless of the explana-
tion, the cumulative evidence indicates that daytime sleepiness
is not a reliable diagnostic criterion for OSA in patients with
many chronic medical disorders including CKD. Further, the
absence of daytime sleepiness should not dissuade the clinician
from considering a diagnosis of OSA in this patient popula-
tion. In the present work, Sleep disorders among CKD
patients, included, insomnia 20(50%), and periodic limb move-
ment (PLM) disorder, it was signiﬁcantly different in the HD
and conservative groups compared with the control group
(P< 0.05). Contributors to insomnia include periodic limb
movement (PLM);and sleep apnea [59,60]; metabolic factors,
including uremia, anemia, hypercalcemia [61,62], bone pain,
and pruritus; anxiety and depression [63,64]; circadian rhythm
disorders, such as delayed sleep phase syndrome [65]; the use of
Sleep disordered breathing in chronic kidney disease patients 125medications that prevent sleep; and poor sleep hygiene, includ-
ing frequent napping during daytime dialysis. Elevated plasma
levels of orexin (a neuropeptide that promotes wakefulness)
[66] and systemic inﬂammation [67,68] may also contribute
to poor sleep among ESRD patients. The diurnal rhythm of
melatonin is disturbed in patients with ESRD, and it is also
related to the degree of kidney dysfunction in patients with
chronic kidney disease (CKD) [69] Some studies have sug-
gested that the timing of the dialysis shift alters the severity
of insomnia, such that insomnia is worse among patients
who are dialyzed in the morning [70,71], but this has not been
shown in all studies [72]. Lugaresi et al. declared that Snoring
would affect 19% to 37% of the CKD population and more
than 50% of ESRD [73]. In our work 20(50%) of CKD were
snorers, There were highly signiﬁcant differences P< 0.001
in the prevalence of reported snoring, among HD compared
with the conservative group. while% of snoring time in TST
was signiﬁcantly higher in the HD and conservative groups
compared with the control group (P< 0.001). Present work
revealed that older age was strongly associated with increased
likelihood of severe SDB in the HD and CKD groups. This
ﬁnding extends established knowledge from the general popu-
lation; SDB occurs in 24% of older men and 56% of older
women [74]. Differences in fat distribution, upper airway anat-
omy, neurochemical control mechanisms, arousal response,
and hormones may underline these age differences in the gen-
eral population [74] and are possibly operational in patients
with renal dysfunction.
In conclusion, sleep related breathing disorders (SDB) tend
to be under-recognized by renal healthcare providers. Objec-
tive polysomnography is required to reliably identify sleep
apnea in the CKD population. Severe OSA is highly prevalent
among advanced CKD & HD. Urea became a stronger predic-
tor of increased AHI. Patients with CKD are commonly
exposed to nocturnal hypoxia related to both unrecognized
sleep apnea and other factors. Further studies are required
to determine whether treatment of sleep apnea and nocturnal
hypoxia improves these clinical outcomes in patients with
CKD. A longitudinal follow-up study is needed to better char-
acterize the natural history of SDB in patients with progressive
CKD. Nephrologists should have a high index of suspicion for
the diagnosis and treatment of SDB in symptomatic CKD and
HD patients. OSA is treatable condition; therefore, additional
studies are necessary to better deﬁne the role of OSA in renal
injury and to identify ways of improving renal outcomes in
CKD.
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